Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation

[1]  B. Becher,et al.  Development, application and computational analysis of high-dimensional fluorescent antibody panels for single-cell flow cytometry , 2019, Nature Protocols.

[2]  C. Niemeyer,et al.  Juvenile myelomonocytic leukemia: who's the driver at the wheel? , 2019, Blood.

[3]  Y. Carmi,et al.  Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti–PD-1 for tumor abrogation , 2018, Proceedings of the National Academy of Sciences.

[4]  Lai Guan Ng,et al.  Dimensionality reduction for visualizing single-cell data using UMAP , 2018, Nature Biotechnology.

[5]  E. Solary,et al.  Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults , 2018, HemaSphere.

[6]  A. Tefferi,et al.  Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management , 2018, American journal of hematology.

[7]  M. Boerries,et al.  Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms , 2018, Science Translational Medicine.

[8]  M. Caligiuri,et al.  Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells , 2018, Nature Medicine.

[9]  G. Botti,et al.  EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients , 2017, Gastroenterology.

[10]  B. Kuster,et al.  K+ Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria. , 2016, Immunity.

[11]  W. Weichert,et al.  RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. , 2016, Cancer cell.

[12]  M. Stratton,et al.  Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents , 2016, Nature Communications.

[13]  K. Ko,et al.  Interactions between Myc and Mediators of Inflammation in Chronic Liver Diseases , 2015, Mediators of inflammation.

[14]  K. Schroder,et al.  A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases , 2015, Nature Medicine.

[15]  C. Niemeyer.  RAS diseases in children , 2014, Haematologica.

[16]  M. Idzko,et al.  The Nlrp3 inflammasome regulates acute graft-versus-host disease , 2013, The Journal of experimental medicine.

[17]  K. Komanduri,et al.  MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. , 2013, Blood.

[18]  R. Cencic,et al.  Targeting protein synthesis in a Myc/mTOR-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival. , 2012, Cancer research.

[19]  M. Loh,et al.  Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. , 2009, Leukemia research.

[20]  Christopher G. King,et al.  STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease. , 2008, Blood.

[21]  A. Prieur,et al.  Cryopyrinopathies: update on pathogenesis and treatment , 2008, Nature Clinical Practice Rheumatology.

[22]  C. Niemeyer,et al.  Non‐hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: A retrospective analysis and definition of response criteria , 2007, Pediatric blood & cancer.

[23]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[24]  H. Forman,et al.  ATP Activates a Reactive Oxygen Species-dependent Oxidative Stress Response and Secretion of Proinflammatory Cytokines in Macrophages* , 2007, Journal of Biological Chemistry.

[25]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[26]  J. Licht,et al.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.

[27]  P. Warde,et al.  Carcinoma of the maxillary antrum: a retrospective analysis of 110 cases. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  S. Akira,et al.  Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. , 1998, Immunity.

[29]  Y. Hayashi,et al.  Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia. , 1997, Leukemia research.

[30]  J. Harbott,et al.  Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) , 1997, Blood.

[31]  J. Harbott,et al.  Chronic myelomonocytic leukemia in childhood. A retrospective analysis of 110 cases. , 1997 .

[32]  E. Goldsmith,et al.  How MAP Kinases Are Regulated (*) , 1995, The Journal of Biological Chemistry.

[33]  C. Bloomfield,et al.  Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia , 1994 .

[34]  G. Brodeur.  The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes. , 1994, The New England journal of medicine.

[35]  Z. Estrov,et al.  Central role of tumour necrosis factor, GM‐CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia , 1992, British journal of haematology.

[36]  C. Marshall,et al.  Analysis of ras gene mutations in childhood myeloid leukaemia , 1991, British journal of haematology.

[37]  C. Dinarello,et al.  Interleukin 1-dependent paracrine granulopoiesis in chronic granulocytic leukemia of the juvenile type. , 1988, The Journal of clinical investigation.

[38]  R. Baehner,et al.  Juvenile "chronic granulocytic" leukemia: a panmyelopathy with prominent monocytic involvement and circulating monocyte colony-forming cells. , 1974, Blood.

[39]  J. Tschopp,et al.  The Inflammasomes , 2010, Cell.

[40]  H. Gawish,et al.  The Prognostic Impact of K-RAS Mutations in Adult Acute Myeloid Leukemia Patients Treated with High Dose Cytarabine. , 2009, Journal of the Egyptian National Cancer Institute.

[41]  R. Arceci.  Hematopoietic Stem Cell Transplantation (HSCT) in Children With Juvenile Myelomonocytic Leukemia (JMML): Results of the EWOG-MDS/EBMT Trial , 2006 .

[42]  E. Lanino,et al.  Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. , 2005, Blood.

[43]  R. Riley,et al.  Reticulocytes and reticulocyte enumeration , 2001, Journal of clinical laboratory analysis.

[44]  C. Bloomfield,et al.  Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. , 1994, Blood.